Literature DB >> 15526523

Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis.

D Grigorie1, Elena Neacşu, Mirela Marinescu, Oana Popa.   

Abstract

Osteoprotegerin (OPG) is a recently identified citokine with an important role in bone remodeling, that acts as a decoy receptor for RANKL; OPG was shown to be an important inhibitor of osteoclast differentiation and activation. Leptin influences bone metabolism by acting on differentiated osteoblasts, having an anabolic effect on bone. The relationship between circulating OPG levels and osteoporosis in postmenopausal women is controversial. Thus, one of the aims of our study was to investigate the relationships between OPG levels and biochemical markers of bone turnover and bone density in women with and without osteoporosis. We have investigated 135 postmenopausal women, including a group with osteoporosis (n=76, mean age 59+/-8 years) and a group with severe osteoporosis (n=31, mean age 64+/-8 years), using healthy postmenopausal women (n=28, mean age 48+/-9 years) as controls. The serum concentrations of OPG were determinated by ELISA. Serum estradiol was measured by Enzyme Immunoassay (EIA). The markers of bone formation and resorption were measured by standard methods. Leptin was measured by ELISA. Bone mineral density at lumbar spine and femoral neck was measured by dual energy x-ray absorptiometry (DEXA). There was a significant positive association between serum OPG levels and age (r=0.27; p<0.001), both in the postmenopausal women as a whole and in the cohort with osteoporosis. Circulating OPG levels were significantly higher in both osteoporotic groups (p<0.005 and p<0.01, respectively) than in the control group. There were no significant associations between serum OPG levels and bone density, bone markers and serum estradiol. Serum leptin levels were significantly associated with age (r=0.18, p<0.03), estradiol (r=0.2, p<0.05) and BMD (r=0.25, p<0.008); there was no significant relationship between leptin and bone turnover markers. We conclude that serum OPG levels increase with age, both in healthy and osteoporotic postmenopausal women. This could represent a possible protective mechanism against bone loss. Serum leptin levels also increase with age and are positively associated with estradiol and BMD and not significantly associated with bone turnover markers.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15526523

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN: 1220-4749


  7 in total

Review 1.  Roles of leptin in bone metabolism and bone diseases.

Authors:  Xu Xu Chen; Tianfu Yang
Journal:  J Bone Miner Metab       Date:  2015-03-18       Impact factor: 2.626

2.  Serum markers of bone turnover in dialyzed patients separated according to age.

Authors:  Alicja E Grzegorzewska; Monika Młot
Journal:  Int Urol Nephrol       Date:  2006       Impact factor: 2.370

Review 3.  Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?

Authors:  Doris Wagner; Astrid Fahrleitner-Pammer
Journal:  Wien Med Wochenschr       Date:  2010-08-16

4.  Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individuals.

Authors:  Todd T Brown; Yun Chen; Judith S Currier; Heather J Ribaudo; Jennifer Rothenberg; Michael P Dubé; Robert Murphy; James H Stein; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07-01       Impact factor: 3.731

5.  Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover.

Authors:  P Oelzner; S Franke; G Lehmann; T Eidner; A Müller; G Wolf; G Hein
Journal:  Clin Rheumatol       Date:  2007-05-31       Impact factor: 2.980

6.  Osteoimmunopathology in HIV/AIDS: A Translational Evidence-Based Perspective.

Authors:  André Barkhordarian; Reem Ajaj; Manisha H Ramchandani; Gary Demerjian; Riana Cayabyab; Sohrab Danaie; Nora Ghodousi; Natasha Iyer; Nicole Mahanian; Linda Phi; Amy Giroux; Ercolano Manfrini; Negoita Neagos; Muniza Siddiqui; Olivia S Cajulis; Xenia M C Brant; Paul Shapshak; Francesco Chiappelli
Journal:  Patholog Res Int       Date:  2011-05-21

7.  Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis.

Authors:  Asieh Mansour; Maryam Aboeerad; Mostafa Qorbani; Amir Pejman Hashemi Taheri; Mohamad Pajouhi; Abbas Ali Keshtkar; Bagher Larijani; Mohammad Reza Mohajeri-Tehrani; Mohammad Reza Ganji
Journal:  BMC Nephrol       Date:  2018-07-11       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.